SenzaGen
5.70 SEK
-4.04 %
Less than 1K followers
SENZA
First North Stockholm
Medical Equipment & Services
Health Care
Overview
Financials & Estimates
Ownership
Investor consensus
-4.04 %
-5.32 %
-6.25 %
-11.21 %
+2.15 %
-18.57 %
-53.85 %
-52.30 %
-86.51 %
Senzagen is a medical technology company. The company develops and carries out genomic in vitro tests, which means that the toxicological ability of various chemicals is not tested on animals but instead in test tubes. The company has developed a technological platform that is used to study the impact of substances produced by actors in the pharmaceutical, cosmetics, and chemical industries. Research and development take place from the head office in Lund.
Read moreMarket cap
168.17M SEK
Turnover
250.89K SEK
Revenue
57.7M
EBIT %
-32.84 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
13/2
2026
Annual report '25
12/5
2026
Interim report Q1'26
12/5
2026
General meeting '26
All
Webcasts
Press releases
3rd party
ShowingAll content types
SenzaGen genomför en riktad nyemission om cirka 17,5 MSEK till den institutionella investeraren Eiffel Investment Group
SenzaGen carries out a directed issue of approximately SEK 17.5 million to the institutional investor Eiffel Investment Group
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
